Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.

@article{Pfister2009OutcomePI,
  title={Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.},
  author={Stefan M. Pfister and Marc Remke and Axel Benner and Frank Mendrzyk and Grischa Toedt and J{\"o}rg Felsberg and Andrea Wittmann and Frauke Devens and Nicolas U Gerber and Stefan Joos and Andreas E. Kulozik and Guido Reifenberger and Stefan Rutkowski and Otmar Dieter Wiestler and Bernhard Radlwimmer and Wolfram Scheurlen and Peter Lichter and Andrey Korshunov},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2009},
  volume={27 10},
  pages={
          1627-36
        }
}
  • S. Pfister, M. Remke, +15 authors A. Korshunov
  • Published 2009
  • Biology, Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Medulloblastoma is the most common malignant brain tumor in children. Current treatment decisions are based on clinical variables. Novel tumor-derived biomarkers may improve the risk stratification of medulloblastoma patients. PATIENTS AND METHODS A model for the molecular risk stratification was proposed from an array-based comparative genomic hybridization (array-CGH) screen (n = 80). Fluorescence in situ hybridization (FISH) analyses for chromosome arms 6q, 17p, and 17q and the MYC… Expand
Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
TLDR
A more tailored subgrouping system based on expression profiles of chromosome 17p, MYCC, and MYCN, which could provide the basis for a novel risk-stratification strategy in pediatric medulloblastoma is suggested. Expand
Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
  • A. Korshunov, M. Remke, +14 authors S. Pfister
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2010
TLDR
Adult MB is distinct from pediatric MB in terms of genomic aberrations and their impact on clinical outcomes, therefore, adult MBs require age-specific risk stratification models and a molecular staging system involving three distinct risk groups based on DNA copy number status of 10q and 17q is proposed. Expand
Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
  • D. Ellison, M. Kocak, +8 authors S. Clifford
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
PURPOSE Medulloblastomas are heterogeneous and include relatively good-prognosis tumors characterized by Wnt pathway activation, as well as those that cannot be successfully treated with conventionalExpand
Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial
TLDR
Routine testing for specific patterns of chromosome 17 imbalance at the cellular level, and MBWNT, provides a strong basis for incorporation into future trials, and is supported as independent prognostic markers in multivariate testing. Expand
Novel amplifications in pediatric medulloblastoma identified by genome-wide copy number profiling
TLDR
The most frequently observed alteration was the combination of 17p loss and 17q gain, which was detected in both high- and standard-risk patients and confirmed its genetic heterogeneity in Medulloblastoma. Expand
MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma
TLDR
This cumulative-risk model defines a patient group characterised by ≥2 independent risk-factors and an extremely poor prognosis (<15% survival), which can be identified straightforwardly using the reported MYC amplification detection methodologies alongside clinical assessments, enabling targeting for novel/intensified therapies in future clinical studies. Expand
Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma
TLDR
In the pooled dataset metastatic disease, incomplete tumor resection and severe anaplasia were associated with poor outcome, while young age at presentation was not prognostically significant and of the chromosomal variables studied, isolated 17p loss and gain of 1q correlated with poor survival. Expand
Biological and clinical heterogeneity of MYCN-amplified medulloblastoma
TLDR
Assessment of disease group and 10q copy-number status may improve risk stratification of this group and may delineate MYCN-MB with the same dismal prognosis as MYC amplified tumors. Expand
Diagnostic Accuracy of a Reduced Immunohistochemical Panel in Medulloblastoma Molecular Subtyping, Correlated to DNA-methylation Analysis.
TLDR
The high concordance of the routine immunohistochemical panel (YAP1, GAB1, OTX2, and β-catenin) and DNA-methylation profiling confirm its utility as a reliable predictive marker of molecular subtype in MBs. Expand
Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.
TLDR
This study explores the clinical utility of testing for idic(17)(p11.2) rearrangements using an assay based on fluorescent in situ hybridization (FISH) and finds it may be useful for risk stratification in standard-risk patients. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
Isochromosome 17q Is a Negative Prognostic Factor in Poor-Risk Childhood Medulloblastoma Patients
TLDR
Medulloblastomas are genetically heterogeneous and can be categorized into separate genetic subgroups by their CNAs using unsupervised cluster analysis and SAM and quantitatively validated those CNAs identified by un supervised clustering that significantly distinguished among the four subgroups. Expand
Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma.
TLDR
CDK6 is identified as a novel molecular marker that can be determined by immunohistochemistry on routinely processed tissue specimens and may facilitate the prognostic assessment of medulloblastoma patients. Expand
Prognostic implications of chromosome 17p deletions in human medulloblastomas
TLDR
It is demonstrated that, while only rare medulloblastomas containTP53 gene mutations or amplification of the c-myc gene, loss of heterozygosity on chromosome 17p is indicative of a significantly worse prognosis among patients with these tumors. Expand
Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients
TLDR
Combined evaluation of novel histopathological features and molecular cytogenetic abnormalities promises to allow stratification of patients with medulloblastoma, such that those likely to be cured will be spared the side effects of maximal therapy, which can be targeted at those with aggressive disease. Expand
Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.
  • J. Biegel, A. Janss, +4 authors P. Phillips
  • Medicine, Biology
  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
TLDR
Clinical use of this factor to distinguish high-risk from standard-risk PNET/Mb populations is not warranted at this time; however, a larger study of the prognostic value of 17p deletion should be considered. Expand
Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91
TLDR
Whereas the collection of fresh-frozen tumor samples remains a major challenge in large clinical trials, routinely processed paraffin-embedded tissue samples can be used to quantitate the prognostic biological markers trkC and c-myc and may lead to improved stratification of treatment for children with medulloblastoma. Expand
Clinical and molecular stratification of disease risk in medulloblastoma
TLDR
The hypothesis that a combination of clinical and molecular factors may afford a more reliable means of assigning disease risk in patients with medulloblastoma is supported, thereby providing a more accurate basis for targeting therapy in children with this disease. Expand
beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee.
TLDR
Nuclear accumulation of beta-catenin appears to be a marker of favorable outcome in medulloblastoma, and should be investigated further in large group-wide trials. Expand
Histopathological and Molecular Prognostic Markers in Medulloblastoma: c‐myc, N‐myc, TrkC, and Anaplasia
TLDR
The association the authors describe between c-myc expression, tumor anaplasia, and worse clinical outcomes provides further evidence for the importance of this oncogene in medulloblastoma pathobiology. Expand
Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma.
TLDR
Central and rapid molecular analysis of frozen medulloblastomas collected from multiple institutions is feasible and ERBB2 expression and clinical risk factors together constitute a highly accurate disease risk stratification tool. Expand
...
1
2
3
4
...